Vyome narrows Q3 loss to $0.13 per share, cash rises to $7M
Vyome Holdings (NASDAQ:HIND) reported a narrower Q3 loss of $0.13 per share, down from $3.06 a year ago. Revenue increased to $57,998 from $34,627, but nine-month revenue fell to $116,544. Cash rose to $6.96M. Operating expenses decreased to $1.05M. The company is developing VT-1953 and appointed a new CFO. The FDA requested more info on its orphan drug designation.
How this was made
The 30-second read
Why it matters
The earnings release provides the first detailed financial snapshot for Q3 2026, highlighting a significant loss reduction but continued cash constraints.
Market read
Micro‑cap biotech earnings with modest loss improvement; limited immediate market impact but relevant for sector‑focused traders.
What to watch
Potential FDA meeting and orphan‑drug designation progress could be catalysts not reflected in the earnings numbers.
Background
Vyome Holdings is a clinical‑stage biopharma developing topical treatments for rare wound conditions.
Ticker impact
Vyome Holdings reported Q3 loss of $0.13 per share, cash $6.96M and revenue $58K, a fresh earnings release for the company.
likely modest upside as the loss narrowed, but limited by low revenue and cash constraints
Quarterly loss improvement is positive, yet the company remains cash‑light and revenue‑poor, suggesting only a small price move.
Market effects
Biopharma micro‑caps may see slight attention as earnings season highlights cash‑flow challenges.
Limited to U.S. biotech investors; no broader regional effect.
Minimal global impact; only relevant to niche biotech investors.
Counterpoint
Despite loss narrowing, the company’s tiny revenue and cash burn could trigger further downside.
Key entities
- companyVyome Holdings, Inc.
Clinical‑stage biopharma reporting Q3 2026 results.
- personJerry Leonard
Newly appointed Chief Financial Officer.


